FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma By Ogkologos - November 13, 2025 465 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AQUILA study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Women at High Risk of Breast Cancer Find it Hard to... April 22, 2021 Breast cancer surgery: ‘I’m proud of the tattoos inked across my... October 21, 2021 FDA Approves Gemtuzumab Ozogamicin for CD33-positive AML in Paediatric Patients June 23, 2020 EMA Recommends Extension of Therapeutic Indications for Irinotecan Hydrochloride Trihydrate April 3, 2024 Load more HOT NEWS Same Breast Cancer, Same Place, Same Treatment. This Mother and Daughter... EMA Recommends Granting a Marketing Authorisation for Ensartinib 3 ways we’re helping teenagers and young adults with cancer Personalised blood test could help predict which lung cancers might return
